90
Participants
Start Date
March 31, 2013
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
givinostat
"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
Charite Research Organization GmbH, Berlin
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico UOS Oncoematologia anziano, Milan
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo
Fondazione I.R.C.C.S.-Policlinico San Matteo, Pavia, Pavia
Ospedale San Bortolo, Vicenza, Vicenza
Azienda Ospedaliero-Universitaria Careggi, Florence, Florence
"Azienda Unità Sanitaria Locale - Presidio Ospedaliero Spirito Santo, Pescara", Pescara
Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Bari
Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico di Bari, Bari
Universitaetsklinikum Freiburg, Innere Medizin I - Haematologie und Onkologie, Freiburg im Breisgau
"Azienda Ospedaliera Universitaria Università degli Studi Federico II, Naple", Naples
"Azienda Ospedaliera Bianchi-Melacrino-Morelli", Reggio Calabria
"Università Campus Bio-Medico, Rome", Rome
Belfast City Hospital, Belfast
Royal Cornwall Hospital, Truro
Lead Sponsor
Italfarmaco
INDUSTRY